Table 4 Clinical characteristics according to the expression of ZEB1
From: Clinical significance of mTOR, ZEB1, ROCK1 expression in lung tissues of pulmonary fibrosis patients
|  | ZEB1 negative(n = 4) | ZEB1 intermediate,strong(n = 26) | p value |
|---|---|---|---|
Age, years, median (range) | 61 (52-74) | 57 (38-72) | 0.362 |
Male sex | 1 (25.0) | 13 (50.0) | 0.602 |
Ever smoker | 2 (50.0) | 9 (34.6) | 0.611 |
FVC, % | 86.0 ± 17.5 | 72.2 ± 14.7 | 0.099 |
DLCO, % | 61.5 ± 19.7 | 63.5 ± 29.1 | 0.892 |
PaO2, mmHg | 88.1 ± 5.5 | 92.7 ± 17.1 | 0.606 |
BAL Neutrophil, % | 37.6 ± 31.6 | 19.3 ± 19.3 | 0.213 |
BAL Lymphocyte, % | 13.3 ± 5.6 | 18.5 ± 10.6 | 0.433 |
Radiologic honeycombing score | 1.5 ± 3.0 | 2.1 ± 2.6 | 0.656 |
Histologic fibrosis score | 1.6 ± 1.3 | 14.0 ± 8.0 | <0.001 |
Δ FVC, mL | 105 ± 487 | - 47 ± 298 | 0.517 |
Δ DLCO, mL/mmHg/min | 2.16 ± 3.54 | - 0.57 ± 1.77 | 0.067 |
Δ FVC, % | 4.8 ± 17.6 | 0.2 ± 13.0 | 0.647 |
Δ DLCO, % | 14.0 ± 21.5 | - 1.8 ± 9.1 | 0.047 |
Survivors | 4 (100) | 20 (76.9) | 0.557 |
mTOR | 1.5 ± 3.0 | 4.6 ± 2.8 | 0.039 |
ROCK1 | 1.3 ± 0.9 | 3.5 ± 2.9 | 0.183 |